Cargando…

Neutralization sensitivity of HIV-1 subtype B’ clinical isolates from former plasma donors in China

BACKGROUND: HIV-1 subtype B’ isolates have been predominantly circulating in China. Their intra- and inter-subtype neutralization sensitivity to autologous and heterologous plasmas has not been well studied. RESULTS: Twelve HIV-1 B’ clinical isolates obtained from patients were tested for their intr...

Descripción completa

Detalles Bibliográficos
Autores principales: OuYang, Yabo, Sun, Jianping, Huang, Yang, Lu, Lu, Xu, Weisi, Hu, Xintao, Hong, Kunxue, Jiang, Shibo, Shao, Yiming, Ma, Liying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599083/
https://www.ncbi.nlm.nih.gov/pubmed/23289760
http://dx.doi.org/10.1186/1743-422X-10-10
_version_ 1782262882259435520
author OuYang, Yabo
Sun, Jianping
Huang, Yang
Lu, Lu
Xu, Weisi
Hu, Xintao
Hong, Kunxue
Jiang, Shibo
Shao, Yiming
Ma, Liying
author_facet OuYang, Yabo
Sun, Jianping
Huang, Yang
Lu, Lu
Xu, Weisi
Hu, Xintao
Hong, Kunxue
Jiang, Shibo
Shao, Yiming
Ma, Liying
author_sort OuYang, Yabo
collection PubMed
description BACKGROUND: HIV-1 subtype B’ isolates have been predominantly circulating in China. Their intra- and inter-subtype neutralization sensitivity to autologous and heterologous plasmas has not been well studied. RESULTS: Twelve HIV-1 B’ clinical isolates obtained from patients were tested for their intra- and inter-subtype neutralization sensitivity to the neutralization antibodies in the plasmas from patients infected by HIV-1 B’ and CRF07_BC subtypes, respectively. We found that the plasmas from the HIV-1 B’-infected patients could potently neutralize heterologous viruses of subtype B’ with mean ID50 titer (1/x) of about 67, but they were not effective in neutralizing autologous viruses of subtype B’ with mean ID50 titer (1/x) of about 8. The plasmas from HIV-1 CRF07_BC-infected patients exhibited weak inter-subtype neutralization activity against subtype B’ viruses with ID50 titer (1/x) is about 22. The neutralization sensitivity of HIV-1 B’ isolates was inversely correlated with the neutralizing activity of plasmas from HIV-1 B’-infected patients (Spearman’s r = −0.657, P = 0.020), and with the number of potential N-glycosylation site (PNGS) in V1-V5 region (Spearman’s r = −0.493, P = 0.034), but positively correlated with the viral load (Spearman’s r = 0.629, P = 0.028). It had no correlation with the length of V1-V5 regions or the CD4+ T cell count. Virus AH259V has low intra-subtype neutralization sensitivity, it can be neutralized by 17b (IC(50): 10μg/ml) and 447-52D (IC(50): 1.6μg/ml), and the neutralizing antibodies (nAbs) in plasma AH259P are effective in neutralizing infection by the primary HIV-1 isolates with different subtypes with ID50 titers (1/x) in the range of 32–396. CONCLUSIONS: These findings suggest that the HIV-1 subtype B’ viruses may mutate under the immune pressure, thus becoming resistant to the autologous nAbs, possibly by changing the number of PNGS in the V1-V5 region of the viral gp120. Some of primary HIV-1 isolates are able to induce both intra- and inter-subtype cross-neutralizing antibody responses.
format Online
Article
Text
id pubmed-3599083
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35990832013-03-17 Neutralization sensitivity of HIV-1 subtype B’ clinical isolates from former plasma donors in China OuYang, Yabo Sun, Jianping Huang, Yang Lu, Lu Xu, Weisi Hu, Xintao Hong, Kunxue Jiang, Shibo Shao, Yiming Ma, Liying Virol J Research BACKGROUND: HIV-1 subtype B’ isolates have been predominantly circulating in China. Their intra- and inter-subtype neutralization sensitivity to autologous and heterologous plasmas has not been well studied. RESULTS: Twelve HIV-1 B’ clinical isolates obtained from patients were tested for their intra- and inter-subtype neutralization sensitivity to the neutralization antibodies in the plasmas from patients infected by HIV-1 B’ and CRF07_BC subtypes, respectively. We found that the plasmas from the HIV-1 B’-infected patients could potently neutralize heterologous viruses of subtype B’ with mean ID50 titer (1/x) of about 67, but they were not effective in neutralizing autologous viruses of subtype B’ with mean ID50 titer (1/x) of about 8. The plasmas from HIV-1 CRF07_BC-infected patients exhibited weak inter-subtype neutralization activity against subtype B’ viruses with ID50 titer (1/x) is about 22. The neutralization sensitivity of HIV-1 B’ isolates was inversely correlated with the neutralizing activity of plasmas from HIV-1 B’-infected patients (Spearman’s r = −0.657, P = 0.020), and with the number of potential N-glycosylation site (PNGS) in V1-V5 region (Spearman’s r = −0.493, P = 0.034), but positively correlated with the viral load (Spearman’s r = 0.629, P = 0.028). It had no correlation with the length of V1-V5 regions or the CD4+ T cell count. Virus AH259V has low intra-subtype neutralization sensitivity, it can be neutralized by 17b (IC(50): 10μg/ml) and 447-52D (IC(50): 1.6μg/ml), and the neutralizing antibodies (nAbs) in plasma AH259P are effective in neutralizing infection by the primary HIV-1 isolates with different subtypes with ID50 titers (1/x) in the range of 32–396. CONCLUSIONS: These findings suggest that the HIV-1 subtype B’ viruses may mutate under the immune pressure, thus becoming resistant to the autologous nAbs, possibly by changing the number of PNGS in the V1-V5 region of the viral gp120. Some of primary HIV-1 isolates are able to induce both intra- and inter-subtype cross-neutralizing antibody responses. BioMed Central 2013-01-05 /pmc/articles/PMC3599083/ /pubmed/23289760 http://dx.doi.org/10.1186/1743-422X-10-10 Text en Copyright ©2013 Ouyang et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
OuYang, Yabo
Sun, Jianping
Huang, Yang
Lu, Lu
Xu, Weisi
Hu, Xintao
Hong, Kunxue
Jiang, Shibo
Shao, Yiming
Ma, Liying
Neutralization sensitivity of HIV-1 subtype B’ clinical isolates from former plasma donors in China
title Neutralization sensitivity of HIV-1 subtype B’ clinical isolates from former plasma donors in China
title_full Neutralization sensitivity of HIV-1 subtype B’ clinical isolates from former plasma donors in China
title_fullStr Neutralization sensitivity of HIV-1 subtype B’ clinical isolates from former plasma donors in China
title_full_unstemmed Neutralization sensitivity of HIV-1 subtype B’ clinical isolates from former plasma donors in China
title_short Neutralization sensitivity of HIV-1 subtype B’ clinical isolates from former plasma donors in China
title_sort neutralization sensitivity of hiv-1 subtype b’ clinical isolates from former plasma donors in china
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599083/
https://www.ncbi.nlm.nih.gov/pubmed/23289760
http://dx.doi.org/10.1186/1743-422X-10-10
work_keys_str_mv AT ouyangyabo neutralizationsensitivityofhiv1subtypebclinicalisolatesfromformerplasmadonorsinchina
AT sunjianping neutralizationsensitivityofhiv1subtypebclinicalisolatesfromformerplasmadonorsinchina
AT huangyang neutralizationsensitivityofhiv1subtypebclinicalisolatesfromformerplasmadonorsinchina
AT lulu neutralizationsensitivityofhiv1subtypebclinicalisolatesfromformerplasmadonorsinchina
AT xuweisi neutralizationsensitivityofhiv1subtypebclinicalisolatesfromformerplasmadonorsinchina
AT huxintao neutralizationsensitivityofhiv1subtypebclinicalisolatesfromformerplasmadonorsinchina
AT hongkunxue neutralizationsensitivityofhiv1subtypebclinicalisolatesfromformerplasmadonorsinchina
AT jiangshibo neutralizationsensitivityofhiv1subtypebclinicalisolatesfromformerplasmadonorsinchina
AT shaoyiming neutralizationsensitivityofhiv1subtypebclinicalisolatesfromformerplasmadonorsinchina
AT maliying neutralizationsensitivityofhiv1subtypebclinicalisolatesfromformerplasmadonorsinchina